Skip to main content
Top
Published in: Hepatology International 5/2023

26-04-2023 | Liver Transplantation | Original Article

Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure

Authors: Serami Murakami, Michio Imamura, Takuro Uchida, Yosuke Suehiro, Maiko Namba, Yasutoshi Fujii, Shinsuke Uchikawa, Yuji Teraoka, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Tomokazu Kawaoka, Daiki Miki, Nelson C. Hayes, Masataka Tsuge, Hiroshi Aikata, Masahiro Ohira, Hideki Ohdan, Shiro Oka

Published in: Hepatology International | Issue 5/2023

Login to get access

Abstract

Aim

Heavy alcohol consumption is the most common etiology of acute-on-chronic liver failure (ACLF) in Japan. In some patients, ACLF is associated with a fatal outcome in less than 6 months. We evaluated the prognosis of patients with alcohol-related ACLF in our cohort and explored the prognostic factors.

Methods

Forty-six patients with alcoholic liver cirrhosis who fulfilled the Japanese diagnostic criteria for ACLF, including those classified as extended and/or probable, were enrolled in this study. Serum concentrations of inflammatory cytokines (interleukin [IL]-1β, IL-6, IL-8, IL-10, IL-12p70 and TNFα) were measured. We assessed prognosis and identified factors associated with survival.

Results

During the median 33-day observation period, 19 patients died, and 3 patients underwent living donor liver transplantation. Cumulative survival rates of patients treated without liver transplantation were 69, 48, 41, and 36% at 1, 3, 6, and 12 months, respectively. Eighteen of the 19 deceased patients died within 6 months after ACLF diagnosis. Serum concentrations of inflammatory cytokines were significantly elevated, and patients who underwent liver transplantation or who died within 6 months after admission had significantly higher serum IL-6 levels than the survival group. Multivariate analysis identified IL-6 > 23.3 pg/mL at admission and model for end-stage liver disease (MELD) score ≥ 25 on day 4 of admission as significant independent factors for mortality within 6 months.

Conclusion

Serum IL-6 level and Day-4 MELD were prognostic factors for alcohol-related ACLF. Early liver transplantation is a potential treatment option for patients whose prognosis is expected to be poor.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014;61:1038–1047CrossRefPubMed Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014;61:1038–1047CrossRefPubMed
2.
go back to reference Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144(7):1426–1437CrossRefPubMed Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144(7):1426–1437CrossRefPubMed
3.
go back to reference Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) 2014. Hepatol Int 2014;8:453–71CrossRefPubMed Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) 2014. Hepatol Int 2014;8:453–71CrossRefPubMed
4.
go back to reference Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut BMJ 2017;66:541–553CrossRef Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut BMJ 2017;66:541–553CrossRef
5.
go back to reference Zhang Q, Li Y, Han T, Nie CY, Cai JJ, Liu H, et al. Comparison of current diagnostic criteria for acute-on-chronic liver failure. PLoS One 2015;10(3):e0122158CrossRefPubMedPubMedCentral Zhang Q, Li Y, Han T, Nie CY, Cai JJ, Liu H, et al. Comparison of current diagnostic criteria for acute-on-chronic liver failure. PLoS One 2015;10(3):e0122158CrossRefPubMedPubMedCentral
6.
go back to reference Nakayama N, Uemura H, Uchida Y, Tomiya T, Ido A, Inoue K, et al. A multicenter pilot survey to clarify the clinical features of patients with acute-on-chronic liver failure in Japan. Hepatol Res 2018;48:303–312CrossRefPubMed Nakayama N, Uemura H, Uchida Y, Tomiya T, Ido A, Inoue K, et al. A multicenter pilot survey to clarify the clinical features of patients with acute-on-chronic liver failure in Japan. Hepatol Res 2018;48:303–312CrossRefPubMed
7.
go back to reference Khanam A, Kottilil S. Acute-on-chronic liver failure: pathophysiological mechanisms and management. Front Med (Lausanne) 2021;8:752875CrossRefPubMed Khanam A, Kottilil S. Acute-on-chronic liver failure: pathophysiological mechanisms and management. Front Med (Lausanne) 2021;8:752875CrossRefPubMed
9.
go back to reference Marroni CA, de Fleck Medeiros A, Fernandes SA, Galant LH, Mucenic M, de Mattos Meine MH, et al. Liver transplantation and alcoholic liver disease: history, controversies, and considerations. World J Gastroenterol 2018;24:2785–2805CrossRefPubMedPubMedCentral Marroni CA, de Fleck Medeiros A, Fernandes SA, Galant LH, Mucenic M, de Mattos Meine MH, et al. Liver transplantation and alcoholic liver disease: history, controversies, and considerations. World J Gastroenterol 2018;24:2785–2805CrossRefPubMedPubMedCentral
10.
go back to reference Im GY, Cameron AM, Lucey MR. Liver transplantation for alcoholic hepatitis. J Hepatol 2019;70:328–334CrossRefPubMed Im GY, Cameron AM, Lucey MR. Liver transplantation for alcoholic hepatitis. J Hepatol 2019;70:328–334CrossRefPubMed
11.
go back to reference Mochida S, Nakayama N, Ido A, Inoue K, Genda T, Takikawa Y, et al. Proposed diagnostic criteria for acute-on-chronic liver failure in Japan. Hepatol Res 2018;48:219–224CrossRefPubMed Mochida S, Nakayama N, Ido A, Inoue K, Genda T, Takikawa Y, et al. Proposed diagnostic criteria for acute-on-chronic liver failure in Japan. Hepatol Res 2018;48:219–224CrossRefPubMed
12.
go back to reference Mochida S, Nakayama N, Terai S, Yoshiji H, Shimizu M, Ido A, et al. Diagnostic criteria for acute-on-chronic liver failure and related disease conditions in Japan. Hepatol Res 2022;52:417–421CrossRefPubMed Mochida S, Nakayama N, Terai S, Yoshiji H, Shimizu M, Ido A, et al. Diagnostic criteria for acute-on-chronic liver failure and related disease conditions in Japan. Hepatol Res 2022;52:417–421CrossRefPubMed
13.
go back to reference Cl J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 2016;64(4):1249–1264CrossRef Cl J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 2016;64(4):1249–1264CrossRef
14.
go back to reference Zhou C, Zhang N, He TT, Wang Y, Wang LF, Sun YQ, et al. High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol 2020;26:4479–4488CrossRefPubMedPubMedCentral Zhou C, Zhang N, He TT, Wang Y, Wang LF, Sun YQ, et al. High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol 2020;26:4479–4488CrossRefPubMedPubMedCentral
15.
go back to reference Padia G, Mahajan B, Kumar A, Sonika U, Dahale AS, Sachdeva S, et al. Cystatin C and interleukin-6 for prognosticating patients with acute decompensation of cirrhosis. JGH Open 2021;5:459–464CrossRefPubMedPubMedCentral Padia G, Mahajan B, Kumar A, Sonika U, Dahale AS, Sachdeva S, et al. Cystatin C and interleukin-6 for prognosticating patients with acute decompensation of cirrhosis. JGH Open 2021;5:459–464CrossRefPubMedPubMedCentral
16.
go back to reference Agbim U, Sharma A, Maliakkal B, Karri S, Yazawa M, Goldkamp W, et al. Outcomes of liver transplant recipients with acute-on-chronic liver failure based on EASL-CLIF consortium definition: a single-center study. Transplant Direct 2020;6(4):e544CrossRefPubMedPubMedCentral Agbim U, Sharma A, Maliakkal B, Karri S, Yazawa M, Goldkamp W, et al. Outcomes of liver transplant recipients with acute-on-chronic liver failure based on EASL-CLIF consortium definition: a single-center study. Transplant Direct 2020;6(4):e544CrossRefPubMedPubMedCentral
17.
go back to reference Marot A, Dubois M, Trépo E, Moreno C, Deltenre P. Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis. PLoS One 2018;13(1):e0190823CrossRefPubMedPubMedCentral Marot A, Dubois M, Trépo E, Moreno C, Deltenre P. Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis. PLoS One 2018;13(1):e0190823CrossRefPubMedPubMedCentral
18.
19.
go back to reference Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365:1790–1800CrossRefPubMed Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365:1790–1800CrossRefPubMed
20.
go back to reference Cai YJ, Dong JJ, Dong JZ, Chen Y, Lin Z, Song M, et al. A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure. Aliment Pharmacol Ther 2017;45:1413–1426CrossRefPubMed Cai YJ, Dong JJ, Dong JZ, Chen Y, Lin Z, Song M, et al. A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure. Aliment Pharmacol Ther 2017;45:1413–1426CrossRefPubMed
21.
go back to reference Wu W, Yan H, Zhao H, Sun W, Yang Q, Sheng J, et al. Characteristics of systemic inflammation in hepatitis B-precipitated ACLF: differentiate it from No-ACLF. Liver Int 2018;38:248–257CrossRefPubMed Wu W, Yan H, Zhao H, Sun W, Yang Q, Sheng J, et al. Characteristics of systemic inflammation in hepatitis B-precipitated ACLF: differentiate it from No-ACLF. Liver Int 2018;38:248–257CrossRefPubMed
22.
go back to reference Jalan R, Stadlbauer V, Sen S, Cheshire L, Chang YM, Mookerjee RP. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. Crit Care 2012;16:R227CrossRefPubMedPubMedCentral Jalan R, Stadlbauer V, Sen S, Cheshire L, Chang YM, Mookerjee RP. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. Crit Care 2012;16:R227CrossRefPubMedPubMedCentral
23.
go back to reference Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015;62:243–252CrossRefPubMed Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015;62:243–252CrossRefPubMed
24.
go back to reference Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol 2015;63:1272–1284CrossRefPubMed Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol 2015;63:1272–1284CrossRefPubMed
25.
go back to reference Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–454CrossRefPubMed Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–454CrossRefPubMed
26.
go back to reference Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol 2016;64:1403–1415CrossRefPubMed Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol 2016;64:1403–1415CrossRefPubMed
27.
go back to reference Xiang X, Feng D, Hwang S, Ren T, Wang X, Trojnar E, et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. J Hepatol 2020;72:736–745CrossRefPubMed Xiang X, Feng D, Hwang S, Ren T, Wang X, Trojnar E, et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. J Hepatol 2020;72:736–745CrossRefPubMed
28.
go back to reference Mayr U, Lukas M, Elnegouly M, Vogt C, Bauer U, Ulrich J, et al. Ascitic interleukin 6 is associated with poor outcome and spontaneous bacterial peritonitis: a validation in critically ill patients with decompensated cirrhosis. J Clin Med 2020;9:1–15CrossRef Mayr U, Lukas M, Elnegouly M, Vogt C, Bauer U, Ulrich J, et al. Ascitic interleukin 6 is associated with poor outcome and spontaneous bacterial peritonitis: a validation in critically ill patients with decompensated cirrhosis. J Clin Med 2020;9:1–15CrossRef
Metadata
Title
Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure
Authors
Serami Murakami
Michio Imamura
Takuro Uchida
Yosuke Suehiro
Maiko Namba
Yasutoshi Fujii
Shinsuke Uchikawa
Yuji Teraoka
Hatsue Fujino
Atsushi Ono
Takashi Nakahara
Eisuke Murakami
Wataru Okamoto
Masami Yamauchi
Tomokazu Kawaoka
Daiki Miki
Nelson C. Hayes
Masataka Tsuge
Hiroshi Aikata
Masahiro Ohira
Hideki Ohdan
Shiro Oka
Publication date
26-04-2023
Publisher
Springer India
Published in
Hepatology International / Issue 5/2023
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10532-x

Other articles of this Issue 5/2023

Hepatology International 5/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.